ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

Related Keywords

Houston , Texas , United States , Genentech Roche , Morphosys Incyte , Jason Westin , Lymphoma Clinical Research Program , Janssen Scientific Affairs , Genentech , Novartis , Astrazeneca , Bristol Myers Squibb , Department Of Lymphoma , University Of Texas Md Anderson Cancer Center , New England Journal , Aggressive Lymphoma , Cancer Center , Bristol Myers , Iksuda Therapeutics , Monte Rosa Therapeutics , Axi Cel , Axicabtagene Ciloleucel , Cart Cell Therapy , Dlbcl , Largeb Cell Lymphoma , Lymphoma , Zuma 7 Trial , Pasco , Asco Annual Meeting , New England Journal Of Medicine , D , The University Of Texas Md Anderson Cancer Center , Md Anderson ,